【摘 要】
：
Background:The cysteine protease inhibitor Cystatin C (CstC) is linked to diseases in both quantity and quality.Low extracellular CstC is associated with elevated protease activity in cancer,arthritis
【机 构】
：
Division of Immunology,The Walter and Eliza Hall Institute of Medical Research,Melbourne, VIC 3052,
【出 处】
：
中华医学生物免疫学会第二届学术年会
论文部分内容阅读
Background:The cysteine protease inhibitor Cystatin C (CstC) is linked to diseases in both quantity and quality.Low extracellular CstC is associated with elevated protease activity in cancer,arthritis,atherosclerosis,aortic aneurism and emphysema,whereas abnormal formation of non-inhibitory CstC dimers and aggregates by a mechanism known as domain swapping can cause amyloid angiopathy.
其他文献
We report the identification and characterization of a five-carbon protein posttranslationai modification(PTM)called lysine glntarylation(Kglu).This protein modification was detected by immunoblot and
Firstly,he analyzes situations regarding development of regional medical information platforms at home and abroad,which lays a foundation for the research of big data; secondly,he analyzes challenges
目的:食管癌是最常见的消化道恶性肿瘤之一.近年来,过继性免疫细胞治疗在抑制食管癌复发转移中取得了良好的临床疗效.但也有文献报道部分患者对该治疗无应答.动物实验结果显示,效应性T淋巴细胞向肿瘤组织的归巢能力是过继免疫治疗发挥疗效的决定因素之一.趋化因子在淋巴细胞的体内迁移运动中起重要作用,因此研究鉴定T淋巴细胞向食管癌组织归巢中的关键趋化因子对于改进过继性细胞免疫治疗有着重要意义.本研究筛选食管癌患
Objective:The aim of this meta-analysis of data from phase Ⅲ studies is to characterize efficacy and safety of bortezomib-based versus nonbortezomib-based post-transplantation therapy in patients with
目的：研究HCV慢性感染者外周血粒系髓源抑制细胞(G-MDSC)对干扰素联合利巴韦林抗病毒治疗临床疗效的影响。方法：采用前瞻性队列研究，收集112例初次接受PEG-IFN-α联合利巴韦林抗病毒治疗的HCV慢性感染者(1b基因型)治疗前及停药24周时外周血，比较G-MDSC与HCV-RNA载量、血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、谷氨酰转肽酶(GGT)、血清白蛋白(ALB)及持久病毒学应
目的 观察细胞因子诱导的杀伤细胞(CIK细胞)与同源树突状细胞(DC细胞)共培养后诱导形成的DCIK细胞的体外细胞毒活性及其治疗肝癌的近期临床疗效、免疫学活性及副反应。方法 收录37例晚期肝癌患者,体外诱导出DC和CIK细胞共培养,诱导形成DCIK细胞,流式分析检测其表型,MTT法检测其体外对人肝癌SMCC-7721和HepG2细胞的杀伤活性。所有患者均接受一定剂量的DCIK细胞过继免疫治疗,观察
Background/Aims:To observe the clinical efficacy of anti-HBV-DC vaccine,the dendritic cells originating from peripheral blood mononuclear cells(PBMC) sensitized by HBsAg,in combination with lamivudine
Background/Aims:To observe the clinical efficacy of anti-HBV-DC vaccine,the dendritic cells originating from peripheral blood mononuclear cells(PBMC) sensitized by HBsAg,in combination with thymosin-α
Background/Aims:To observe the clinical efficacy of anti-HBV-DC vaccine,the dendritic cells originating from peripheral blood mononuclear cells(PBMC) sensitized by HBsAg,in combination with thymosin-α
Background/Aims:To observe the clinical efficacy of anti-HBV-DC vaccine,the dendritic cells originating from peripheral blood mononuclear cells(PBMC) sensitized by HBsAg,in combination with lamivudine